Journal of Biomedical and Pharmaceutical Research

Artificial Intelligence in Drug Discovery and Development

2026-03-09T12:12:22+00:00

Artificial Intelligence (AI) is rapidly transforming drug discovery and development by improving efficiency, accuracy, and speed. Traditional drug development is a lengthy and costly process that may take 10-15 years and require billions of dollars to bring a single drug to market. AI helps overcome these limitations by analysing large biological datasets, predicting outcomes, and supporting decision- making throughout different stages of drug development. Machine learning and generative AI models assist in target identification, de novo drug design, virtual screening, lead optimisation, and prediction of ADEMT properties, thereby reducing late- stage failures and improving overall success rates. AI also plays an important role in clinical trial optimisation through better patient selection, real-time monitoring, and outcome prediction. Growing investments and high adoption rates in the pharmaceutical industry highlight the expanding AI market and its economic impact. Despite its advantages, challenges such as data quality issues, high implementation costs, lack of interpretability, ethical concerns, and regulatory complexities remain significant. In India, AI-based drug discovery is guided by CDSCO regulations, ICMR ethical guidelines, NDCTR 2019, and the Digital Personal Data Protection Act, 2023 to ensure safety and compliance. Overall, AI has strong potential to revolutionize pharmaceutical research by accelerating innovation, reducing costs, and enabling personalized medicine.

Keywords: Artificial Intelligence (AI), Drug Discovery, Molecular Design, validation.

Pharmacological Strategies in Cancer Management A Comprehensive Review

2026-03-09T12:27:54+00:00

Cancer is a deadly disease and is the major cause of death worldwide. According to WHO cancer accounts for nearly 10 million deaths in 2020 or about 1in 6 deaths. The impact of factors is widespread, affecting various organs and tissues inthe body. The types of cancer such as breast, brain, lung, kidney, colorectal, lymphoma, as well as skin represent a diverse range of malignancies. The risk factors for developing cancer can include genetic factors, environmental exposures (such as tobacco smoke, ultraviolet radiation, and certain chemicals) lifestyle factors (such as diet and physical activity) and infections. The hallmarks of cancer represent a set of characteristics or capabilities that are commonly acquired by cells during the development of cancer. Multidrug resistance in cancerous cells is their ability to withstand the effects of multiple chemotherapeutic drugs, even if these drugs have different structures. The various Nano-drug delivery systems have been explored as a strategy to overcome multidrug resistance in cancer treatment.

Keywords: Cancer, chemotherapy, radiation, biopsy, tumour, gene mutation

A Review on the Herbal Potential for the Treatment of Peptic Ulcer

2026-04-09T06:03:46+00:00

Ulcer, particularly gastric and duodenal ulcers, have long been a significant concern in the field of gastroenterology. The understanding of their pathophysiology has evolved over the years, leading to the development of various anti-ulcer agents. This abstract provides a brief overview of the mechanisms and therapeutic prospects of anti-ulcer agents. Gastric ulcers are primarily associated with the erosion of the gastric mucosal barrier, which protects the stomach lining from the corrosive effects of gastric acid. Duodenal ulcers, on the other hand, are often linked to excessive acid production. Historically, the mainstay of ulcer treatment involved acid-suppressive medications, such as proton pump inhibitors (PPIs) and histamine receptor antagonists (H2 blockers). These drugs effectively reduced acid secretion and provided relief to patients. Recent advancements in the field have highlighted the crucial role of Helicobacter pylori infection in the development of ulcers. Eradication of this bacterium with antibiotics has become a key component of ulcer management, especially in cases where infection is confirmed. Additionally, mucosal protective agents like sucralfate have gained prominence for their ability to enhance mucosal defense mechanisms and promote ulcer healing. Prostaglandin analogs, such as misoprostol, are used to both reduce acid secretion and promote mucosal protection. In recent years, research has focused on novel therapeutic approaches, including the use of growth factors and stem cell-based therapies to accelerate ulcer healing. Furthermore, the identification of new targets within the inflammatory and oxidative stress pathways has opened up exciting avenues for drug development. In conclusion, the treatment landscape for ulcers has evolved significantly from merely suppressing gastric acid. It now encompasses a multifaceted approach that includes antimicrobial therapy, mucosal protection, and emerging regenerative strategies. These developments hold promise for improved management and enhanced outcomes for patients with ulcers. Please note that this abstract provides a general overview, and the specific details and advancements in the field of anti-ulcer agents may have evolved since my last knowledge update in September 2021.

Keyword: Peptic ulcer disease (PUD), Gastric ulcer, Duodenal ulcer, Helicobacter pylori Gastric acid secretion, Mucosal barrier, Proton pump inhibitors (PPIs), H2 receptor antagonists.